相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions
Peggy J. de Vos van Steenwijk et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers
Kelly Barrios et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Reducing HPV-Associated Cancer Globally
Douglas R. Lowy et al.
CANCER PREVENTION RESEARCH (2012)
A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18
Stephen E. Goldstone et al.
EXPERT REVIEW OF VACCINES (2012)
Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer
Peng Guan et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis
Catherine de Martel et al.
LANCET ONCOLOGY (2012)
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Matti Lehtinen et al.
LANCET ONCOLOGY (2012)
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler et al.
LANCET ONCOLOGY (2012)
Recombinant Lipidated HPV E7 Induces a Th-1-Biased Immune Response and Protective Immunity against Cervical Cancer in a Mouse Model
Chiung-Yi Huang et al.
PLOS ONE (2012)
Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses
Mark L. Bagarazzi et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice
Sun-Woo Yoon et al.
VACCINE (2012)
Cellular transformation by human papillomaviruses: Lessons learned by comparing high- and low-risk viruses
Aloysius J. Klingelhutz et al.
VIROLOGY (2012)
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine up to 8.4 years of follow-up
Cecilia M. Roteli-Martins et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Lm-LLO-Based Immunotherapies and HPV-Associated Disease
Anu Wallecha et al.
JOURNAL OF ONCOLOGY (2012)
New Developments in Therapeutic HPV Vaccines
Jiaying Lin et al.
CURRENT OBSTETRICS AND GYNECOLOGY REPORTS (2012)
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
Elmar A. Joura et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy
Jean-Luc Brun et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors
Chao-Yi Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11
Mark Matijevic et al.
CELLULAR IMMUNOLOGY (2011)
Control of Cervicovaginal HPV-16 E7-Expressing Tumors by the Combination of Therapeutic HPV Vaccination and Vascular Disrupting Agents
Qi Zeng et al.
HUMAN GENE THERAPY (2011)
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule Results from a randomized study
Barbara Romanowski et al.
HUMAN VACCINES (2011)
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine Follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2011)
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Anna R. Giuliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia
Joel M. Palefsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2
Ebenezer Tumban et al.
PLOS ONE (2011)
The role of HPV in head and neck cancer and review of the HPV vaccine
Gypsyamber D'Souza et al.
PREVENTIVE MEDICINE (2011)
Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection
Tae Heung Kang et al.
VACCINE (2011)
A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice
Milaid Granadillo et al.
VACCINE (2011)
Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
Shiwen Peng et al.
JOURNAL OF BIOMEDICAL SCIENCE (2011)
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia
S. Daayana et al.
BRITISH JOURNAL OF CANCER (2010)
Bryostatin-I: A dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine
Weili Yan et al.
CYTOKINE (2010)
Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia
Koenraad Van Doorslaer et al.
GYNECOLOGIC ONCOLOGY (2010)
Measuring serum antibody to human papillomavirus following infection or vaccination
Ian H. Frazer
GYNECOLOGIC ONCOLOGY (2010)
Beyond Cervical Cancer: Burden of Other HPV-Related Cancers Among Men and Women
Anil K. Chaturvedi
JOURNAL OF ADOLESCENT HEALTH (2010)
Current Status of Human Papillomavirus Vaccines
Barbara Ma et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2010)
Perspectives for Preventive and Therapeutic HPV Vaccines
Ken Lin et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2010)
Papillomavirus Prophylactic Vaccines: Established Successes, New Approaches
M. Saveria Campo et al.
JOURNAL OF VIROLOGY (2010)
Efficient secretion of a modified E7 protein from human papilloma virus type-16 by Lactococcus lactis
D. Quistian-Martinez et al.
LETTERS IN APPLIED MICROBIOLOGY (2010)
Fewer shots proposed to increase uptake of HPV vaccine
Kirsten Dorans
NATURE MEDICINE (2010)
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
Marij J. P. Welters et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection
Subhashini Jagu et al.
VACCINE (2010)
Carrageenan as an adjuvant to enhance peptide-based vaccine potency
Yu-Qian Zhang et al.
VACCINE (2010)
Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7
Katsuyuki Adachi et al.
VACCINE (2010)
Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7
Jerri do Carmo Caldeira et al.
VACCINE (2010)
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments
Hans-Ulrich Bernard et al.
VIROLOGY (2010)
Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
Chi-Mu Chuang et al.
JOURNAL OF BIOMEDICAL SCIENCE (2010)
Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarixA®
Tino F. Schwarz
ADVANCES IN THERAPY (2009)
Interferon for the treatment of genital warts: a systematic review
Jin Yang et al.
BMC INFECTIOUS DISEASES (2009)
Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts
Chih-Wen Tseng et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Costimulation as a Platform for the Development of Vaccines: A Peptide-Based Vaccine Containing a Novel Form of 4-1BB Ligand Eradicates Established Tumors
Rajesh K. Sharma et al.
CANCER RESEARCH (2009)
A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3
Cornelia L. Trimble et al.
CLINICAL CANCER RESEARCH (2009)
Human Papillomavirus in Head and Neck Cancer: Its Role in Pathogenesis and Clinical Implications
Christine H. Chung et al.
CLINICAL CANCER RESEARCH (2009)
Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions
Georges Coremans et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Currently approved prophylactic HPV vaccines
Diane M. Harper
EXPERT REVIEW OF VACCINES (2009)
Development of an HPV vaccine for a broad spectrum of high-risk types
Tadahito Kanda et al.
HUMAN VACCINES (2009)
Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2009)
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection
Balasubramanyam Karanam et al.
IMMUNOLOGY AND CELL BIOLOGY (2009)
A Randomized, Placebo-Controlled, Dose-Escalation Study to Determine the Safety, Tolerability, and Immunogenicity of an HPV-16 Therapeutic Vaccine in HIV-Positive Participants With Oncogenic HPV Infection of the Anus
Jonathan S. Anderson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Antibody Responses in Oral Fluid after Administration of Prophylactic Human Papillomavirus Vaccines
Ali Rowhani-Rahbar et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Human Papillomaviruses and the Interferon Response
Melanie Beglin et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2009)
Assessing the HPV Vaccine: Researchers Confront Complex Interplay of Factors
Rabiya S. Tuma
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines
Subhashini Jagu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines
Christina Schellenbacher et al.
JOURNAL OF VIROLOGY (2009)
Analysis of Modified Human Papillomavirus Type 16 L1 Capsomeres: the Ability To Assemble into Larger Particles Correlates with Higher Immunogenicity
Lysann Schaedlich et al.
JOURNAL OF VIROLOGY (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Clinician's guide to human papillomavirus immunology: knowns and unknowns
Mark H. Einstein et al.
LANCET INFECTIOUS DISEASES (2009)
Electroporation for the Delivery of DNA-based Vaccines and Immunotherapeutics: Current Clinical Developments
Angela M. Bodles-Brakhop et al.
MOLECULAR THERAPY (2009)
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia.
Gemma G. Kenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding
Rhonda C. Kines et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Molecular Mechanisms of Human Papillomavirus-Induced Carcinogenesis
Michael Lehoux et al.
PUBLIC HEALTH GENOMICS (2009)
The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix
Paulo Cesar Maciag et al.
VACCINE (2009)
Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline
Mark Schiffman et al.
Infectious Agents and Cancer (2009)
Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects
Chi-Mu Chuang et al.
JOURNAL OF BIOMEDICAL SCIENCE (2009)
Development of an Adenoviral Vaccine Against E6 and E7 Oncoproteins to Prevent Growth of Human Papillomavirus-Positive Cancer
Dong Wook Lee et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2008)
Induction of tumor-specific CD4+ and CD8+ T-Cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine
Marij J. P. Welters et al.
CLINICAL CANCER RESEARCH (2008)
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows lowtoxicity and robust immunogenicity
Gemma G. Kenter et al.
CLINICAL CANCER RESEARCH (2008)
Pretreatment with cisplatin enhances E7-specific CD8+ T-cell mediated antitumor immunity induced by DNA vaccination
Chih-Wen Tseng et al.
CLINICAL CANCER RESEARCH (2008)
Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment
Simona Venturoli et al.
JOURNAL OF MEDICAL VIROLOGY (2008)
Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes
Kazunari Kondo et al.
JOURNAL OF MEDICAL VIROLOGY (2008)
Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+T-cell-mediated antitumor immunity induced by DNA vaccination
Chih-Wen Tseng et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2008)
Molecular epidemiology of human papillomavirus
Talia Hoory et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2008)
Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors
Duane A. Sewell et al.
VACCINE (2008)
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
John T. Schiller et al.
VACCINE (2008)
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: A phase I escalating-dose trial
Alessandro D. Santin et al.
JOURNAL OF VIROLOGY (2008)
A protective and broadly cross-neutralizing epitope of human papillomavirus L2
Ratish Gambhira et al.
JOURNAL OF VIROLOGY (2007)
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2
Ratish Gambhira et al.
JOURNAL OF VIROLOGY (2007)
Salmonella enterica serovar Typhi Ty2la expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever
Dominique Fraillery et al.
CLINICAL AND VACCINE IMMUNOLOGY (2007)
A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia
L. D. Roman et al.
GYNECOLOGIC ONCOLOGY (2007)
Induction of CD4-Independent E7-specific CD8+ memory response by heat shock fusion protein
Hongwei Liu et al.
CLINICAL AND VACCINE IMMUNOLOGY (2007)
Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice
Jorge G. Gomez-Gutierrez et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen et al.
LANCET (2007)
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ:: a combined analysis of four randomised clinical trials
L. Villa et al.
LANCET (2007)
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials
Elmar A. Joura et al.
LANCET (2007)
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Suzanne M. Garland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination
Tae Heung Kang et al.
CANCER RESEARCH (2007)
MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma - A phase I/II study
Antonio Albarran y Carvajal et al.
BIODRUGS (2007)
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III
Mark H. Einstein et al.
GYNECOLOGIC ONCOLOGY (2007)
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
Sandra L. Giannini et al.
VACCINE (2006)
Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion
Pirouz Daftarian et al.
VACCINE (2006)
Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine
E. Garcia-Hernandez et al.
CANCER GENE THERAPY (2006)
A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals
Joel M. Palefsky et al.
AIDS (2006)
Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial
AN Fiander et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Molecular biology of human papillomavirus infection and cervical cancer
John Doorbar
CLINICAL SCIENCE (2006)
Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis
M Kyrgiou et al.
LANCET (2006)
Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: Therapeutic effect against cervical cancer
ZR Cui et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects
CW Liao et al.
CANCER RESEARCH (2005)
HspE7 treatment of pediatric recurrent respiratory papillomatosis: Final results of an open-label trial
CS Derkay et al.
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY (2005)
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2
DV Pastrana et al.
VIROLOGY (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Human papillomavirus type 16 E7 peptide38-61 linked with an immunoglobulin G fragment provides protective immunity in mice
Y Qin et al.
GYNECOLOGIC ONCOLOGY (2005)
Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus
CMC Gutierrez et al.
HUMAN GENE THERAPY (2004)
ZYC101a for treatment of high-grade cervical intralepithelial neoplasia: A randomized controlled trial
F Garcia et al.
OBSTETRICS AND GYNECOLOGY (2004)
Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes
MC Cassetti et al.
VACCINE (2004)
Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin
CJ Hsieh et al.
VACCINE (2004)
ISCOMATRIX™ adjuvant:: an adjuvant suitable for use in anticancer vaccines
TJ Stewart et al.
VACCINE (2004)
Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)
EJ Davidson et al.
VACCINE (2004)
Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia
S Hallez et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX™ adjuvant in women with cervical intraepithelial neoplasia
IH Frazer et al.
VACCINE (2004)
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
DM Harper et al.
LANCET (2004)
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination
LJC Smyth et al.
CLINICAL CANCER RESEARCH (2004)
Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA
EE Sheets et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2003)
Epidemiologic classification of human papillomavirus types associated with cervical cancer
N Muñoz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A controlled trial of a human papillomavirus type 16 vaccine
LA Koutsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein
ME Embers et al.
JOURNAL OF VIROLOGY (2002)
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides
S Zwaveling et al.
JOURNAL OF IMMUNOLOGY (2002)
Papillomaviruses and cancer: From basic studies to clinical application
H zur Hausen
NATURE REVIEWS CANCER (2002)
2001 consensus guidelines for the management of women with cervical cytological abnormalities
TC Wright et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Activity of HspE7, a novel immunotherapy, in patients with anogenital warts
SE Goldstone et al.
DISEASES OF THE COLON & RECTUM (2002)
Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8+ T-cell responses that home to the tumor site
A Lamikanra et al.
JOURNAL OF VIROLOGY (2001)
Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer
M Adams et al.
VACCINE (2001)
Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7
NR Chu et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes
RBS Roden et al.
VIROLOGY (2000)
Imiquimod, a topical immune response modifier, induces migration of Langerhans cells
H Suzuki et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2000)
Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
ME Ressing et al.
JOURNAL OF IMMUNOTHERAPY (2000)
分享论文
